Drugs / Pegylated interferon alfa-2b
Pegylated interferon alfa-2b
also known as
PegIntron · PEG-IFN alpha-2b · PEG-IFN · PEG-interferon-α · pegylated interferon α-2b · SCH 54031
Trials 19
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00886457 | Apr 2009 → Aug 2010 | cancer | Nevada Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00861406 | Mar 2009 → Feb 2017 | melanoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00142103 | Sep 2005 → Feb 2007 | chronic hepatitis C virus infection | Pfizer | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT05395507 | Jun 2022 → Mar 2025 | essential thrombocythemia | Institute of Hematology & Blood Diseases Hospital, China | Unknown | No outcome recorded |
| Phase 2 | NCT04226950 | Jan 2020 → Oct 2024 | essential thrombocythemia | Institute of Hematology & Blood Diseases Hospital, China | Unknown | No outcome recorded |
| Phase 2 | NCT02155322 | Aug 2014 → Mar 2016 | melanoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00006039 | Dec 1999 → Mar 2001 | lymphoma, small intestine cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2/32 trials · 1 missed | ||||||
| Phase 2/3 | NCT01871662 | Aug 2013 → Feb 2016 | chronic hepatitis C virus infection | Rottapharm | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT03547154 | Oct 1998 → Feb 2001 | chronic myeloid leukemia | Merck Sharp & Dohme LLC | Terminated | Missed primary |
| Phase 35 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT00371761 | Sep 2006 → Feb 2009 | chronic hepatitis B virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00378599 | May 2006 → Jul 2009 | chronic hepatitis C virus infection, cirrhosis of liver | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00308048 | Mar 2004 → Sep 2006 | hepatitis C virus infection | Ullevaal University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00686517 | Dec 2003 → Dec 2010 | hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 3 | NCT00006249 | Jun 2000 → Aug 2003 | cutaneous melanoma | European Organisation for Research and Treatment of Cancer - EORTC | Unknown | Met primary |
| Phase 44 trials | ||||||
| Phase 4 | NCT01364090 | Jun 2012 → Jun 2015 | chronic hepatitis C virus infection | Kirby Institute | Completed | No outcome recorded |
| Phase 4 | NCT01045278 | Apr 2008 → Sep 2013 | hepatitis C virus infection | Region Skane | Completed | No outcome recorded |
| Phase 4 | NCT00686777 | Jan 2008 → Dec 2010 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT00279565 | Aug 2005 → Feb 2007 | chronic hepatitis C virus infection | Indivior Inc. | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07445893 | Apr → Dec 2026 expected | acquired polycythemia vera | Duan Minghui | Recruiting | No outcome recorded |
| Comparator or background therapy12 trials | ||||||
| Phase 2 | NCT02737046 Background | Dec 2016 → Dec 2024 | adult T-cell leukemia/lymphoma | University of Miami | Completed | No outcome recorded |
| Phase 2 | NCT01710501 Background | Dec 2012 → Nov 2013 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00277238 Background | Feb 2006 → Jul 2007 | chronic hepatitis C virus infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT06079879 Comparator | Dec 2023 → Jul 2027 expected | essential thrombocythemia | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03833362 Background | May 2014 → Mar 2016 | chronic hepatitis C virus infection | R-Pharm | Completed | No outcome recorded |
| Phase 3 | NCT01482767 Background | Apr 2012 → Apr 2015 | HIV infectious disease, hepatitis C virus infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT00708500 Background | Aug 2008 → Apr 2010 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT00237484 Background | Jul 2005 → Jun 2011 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00265395 Comparator | Dec 2004 → May 2008 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00230958 Background | Dec 2003 → Jan 2006 | chronic hepatitis C virus infection | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT02168361 Comparator | Dec 2013 → Dec 2014 | chronic hepatitis C virus infection | Center For Hepatitis C, Atlanta, GA | Completed | Met primary |
| Phase 4 | NCT00993122 Comparator | Oct 2009 → Apr 2010 | hepatitis C virus infection | University of Roma La Sapienza | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 33 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegylated interferon alfa2b | “Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life...” PMID 19433686 ↗ May 200930“Phase II Study of Weekly Administered High-Dose Pegylated Interferon Alfa-2B (PEGIntron) in Advanced Stage Low Grade Non-Hodgkin's Lymphoma” NCT00006039 ↗ “patients receive ribavirin (10,4 mg/kg/day) and pegylated interferon alfa-2b (1,5 mcg/kg/week).” NCT00993122 ↗ “Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks” NCT00142103 ↗ “Pegylated interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 24wks” NCT00277238 ↗ |
| Known as | PEG-IFN | “Pegylated-Interferon Alfa 2b (PEG-IFN)” NCT01482767 ↗ |
| Known as | PEG-IFN alpha-2b | “This is an exploratory study and is a Phase 3, single-arm, multi-center, open-label study of pegylated interferon alfa-2b, PEG-IFN alpha-2b (PEG-Intron) and ribavirin (RBV) to...” NCT00378599 ↗2“The EORTC 18991 trial assessed the effect of long-term adjuvant pegylated interferon (Peg-IFN) alpha-2b administered weekly in patients with lymph node-positive melanoma.” PMID 19621225 ↗ Jul 2009 “Peg-IFN alpha-2b monotherapy (1.5 μg/kg/week) for 24 or 12 weeks” PMID 24442928 ↗ Apr 2014 |
| Known as | PEG-interferon-α | “weekly subcutaneous PEG-interferon-α (PEG-Intron)” NCT00886457 ↗ |
| Known as | PegIntron | “Phase II Study of Weekly Administered High-Dose Pegylated Interferon Alfa-2B (PEGIntron) in Advanced Stage Low Grade Non-Hodgkin's Lymphoma” NCT00006039 ↗3“Escalating Doses of Sub-Q Pegylated (PEG) Interferon-alfa 2B (PEG-Intron)” NCT00886457 ↗ “Pegylated Interferon-Alfa 2b (PEG Intron)” NCT00861406 ↗ “Pegylated interferon alfa-2b (PegIntron)” NCT00371761 ↗ |
| Known as | pegylated interferon α-2b | “a 24-week course of pegylated interferon α-2b versus a 12-week course of pegylated interferon α-2b alone or with ribavirin” PMID 24442928 ↗ Apr 2014 |
| Known as | SCH 54031 | “Pegylated interferon alfa-2b (SCH 54031)” NCT00708500 ↗ |
| Modality | Protein / enzyme biologic | “Biological: Pegylated interferon alfa-2b” NCT00686517 ↗ |
| Route | Subcutaneous | “Patients receive pegylated interferon alfa-2b subcutaneously once weekly for 6 months” NCT00006039 ↗ |